Terms ending in 2037
Every in-force patent on Chemocentryx, Inc.'s record whose computed term ends in 2037, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,285,138 | Method of Treating C3 Glomerulopathy In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 11,779,576 | Method of Treating C3 Glomerulopathy In force · High confidence | Chemocentryx Inc. | In force | High confidence | |
| US 10,421,748 | 2-Oxindole Compounds In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 10,759,789 | 2-Oxindole Compounds In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 11,434,230 | 2-Oxindole Compounds In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 12,139,475 | 2-Oxindole Compounds In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 10,329,314 | SOLUBLE C5aR ANTAGONISTS In force · Medium confidence | Chemocentryx, Inc. | In force | Medium confidence | |
| US 10,487,098 | SOLUBLE C5aR ANTAGONISTS In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 11,254,695 | SOLUBLE C5aR ANTAGONISTS In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 10,568,870 | Reducing Tumor Burden by Administering CCR1 Antagonists in Combination with PD-1 Inhibitors or PD-L1 Inhibitors In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| 16 more term ends in 2037 · Pro | |||||
10 of 26 patents shown. Soonest term end first, then patent number.
Pro members see all 26.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.